奥沙利铂联合长春瑞滨治疗铂耐药卵巢癌患者的临床研究

Clinical Research of Combined Therapy with Vinorelbine and Oxaliplatin for Platinum Resistance in Patients with Ovarian Cancer

目的研究奥沙利铂联合长春瑞滨治疗铂耐药卵巢癌患者的临床效果。方法选取铂耐药卵巢癌患者78例,根据数字随机量表法分为观察组及对照组,各39例。对照组患者给予伊立替康治疗,观察组则给予奥沙利铂联合长春瑞滨治疗。对比2组效果。结果 2组治疗后RR率差异无统计学意义(P>0.05)。2组各项不良反应发生率对比,差异均无统计学意义(P均>0.05)。观察组6个月体质量减轻>10%的发生率为33.33%(13/39),显著低于对照组的69.23%(27/39),差异有统计学意义(P<0.05)。观察组无进展生存期及总生存期分别为(32.2±7.8)周、(76.8±21.3)周,均显著高于对照组的(22.8±6.3)周、(61.6±14.2)周,差异均有统计学意义(P均<0.05)。结论奥沙利铂联合长春瑞滨治疗铂耐药卵巢癌具有较好疗效,且不会增加不良反应发生率,可延长患者生命。

Objective To study the efficacy of the combined therapy with vinorelbine and oxaliplatin for platinum resistance in patients with ovarian cancer. Methods 78 cases of patients with platinum-resistant ovarian cancer,according to the digital random scaling were divided into the observation group and the control group,39 cases in each group. The control group was given irinotecan for the treatment,the observation group were given oxaliplatin and vinorelbine treatment,compared the 2 groups of effect. Results RR rates of the 2 groups had no significant difference after treatment（ P 〉 0. 05）. There had no significant difference in the incidence of adverse reactions（ P 〉 0. 05）. In the observation group,6 months body quality 〉 10% rate was 10%（ 13/39）,which was significantly lower than the control group,69. 23%（ 27/39）,the difference was statistically significant（ P 〈0. 05）. In the observation group,progression-free survival and overall survival were respectively（ 32. 2 ± 7. 8）,（ 76. 8 ± 21. 3）weeks,which were significantly higher than that of the control group（ 22. 8 ± 6. 3）,（ 61. 6 ± 14. 2） weeks,the differences were statistically significant（ all P 〈 0. 05）. Conclusion Combined therapy with Vinorelbine and oxaliplatin for platinum-resistant ovarian cancer has good curative effect,and will not increase the incidence of adverse reaction,can prolong patients’ life.